Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...
Recent events have shifted perspective on responsibility and priority.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback